LSTA

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.

Wall Street analysts forecast LSTA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LSTA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lisata Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Lisata Therapeutics Inc. EPS for the last quarter amounts to -0.49 USD, decreased -16.95 % YoY.

Lisata Therapeutics Inc (LSTA) has 26 emplpoyees as of January 10 2026.

Today LSTA has the market capitalization of 17.38M USD.